EPITHALON 10mg

CAS NO：307297-39-8
Key Words：Ala-Glu-Asp-Gly
Molecular Formula: C14H22N4O9
Molecular Weight: 390.35
Appearance：white powder
Storage：2-8°
Purity: ≥99

Epithalon, a synthetic tetrapeptide composed of alanine, glutamic acid, aspartic acid, and glycine, has been the subject of significant scientific research due to its potential in various therapeutic areas. It was developed by a research team led by Professor Vladimir Khavinson of the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s​​.

One of the primary mechanisms of action of Epithalon is the upregulation of telomerase activity and the elongation of telomeres. This effect has led to research in life extension, anti-aging, and the inhibition of tumorigenesis. It’s known to regulate gene expression and protein synthesis, with the potential to suppress genes like CCl11 and HMGB1.

Epithalon has also been explored as a potential treatment for rheumatoid arthritis and ulcerative colitis due to its ability to regulate biomolecules involved in the inflammatory process, such as cytokines and C-reactive protein. Additionally, it has been investigated as a regulator of the sleep cycle by increasing levels of melatonin and endogenous gonadotropic hormones, which play a role in reproductive function but naturally decline with age​​.

Clinical trials outside of Russia have classified Epithalon as a research chemical. It’s used in Russia to treat menopause-related symptoms, anovulatory infertility, and hormone-dependent tumors. However, the bulk of research involving Epithalon and epithalamin has been conducted in Russia, and independent confirmation of these studies is limited​​.

Studies have shown that Epithalon can decrease levels of DNA damage, stimulate cortical neurons, increase levels of the DNA-binding protein phosphor-CREB, and improve antioxidant defense systems. Preclinical studies in rats and cancer-prone mice suggest that Epithalon may have utility in cancer prevention, including inhibiting neoplasm development and reducing the size of breast adenocarcinomas​​.

Safety studies indicate that Epithalon is well-tolerated with no severe adverse effects in test subjects. A 15-year follow-up study on subjects who received up to six courses of epithalamin treatment showed no adverse events and a significantly lower mortality rate than the control group.